Phase I Clinical Study of ZYAN1, A Novel Prolyl-Hydroxylase (PHD) Inhibitor to Evaluate the Safety, Tolerability, and Pharmacokinetics Following Oral Administration in Healthy Volunteers

OBJECTIVE: This phase I study of ZYAN1 was conducted to evaluate the safety, tolerability, and pharmacokinetics following oral administration in healthy volunteers. METHODS: The study was a randomized, double-blind, placebo-controlled phase I study carried out in two parts in addition to a third par...

Descripción completa

Detalles Bibliográficos
Autores principales: Kansagra, Kevinkumar A., Parmar, Deven, Jani, Rajendra H., Srinivas, Nuggehally R., Lickliter, Jason, Patel, Harilal V., Parikh, Devang P., Heading, Heather, Patel, Hardik B., Gupta, Rahul J., Shah, Chintan Y., Patel, Maulik R., Dholakia, Vyom N., Sukhadiya, Raghav, Jain, Mukul R., Parmar, Krupi V., Barot, Kinjal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2017
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5766731/
https://www.ncbi.nlm.nih.gov/pubmed/28508936
http://dx.doi.org/10.1007/s40262-017-0551-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5766731/
https://www.ncbi.nlm.nih.gov/pubmed/28508936
http://dx.doi.org/10.1007/s40262-017-0551-3

Ejemplares similares